Metformin can induce abnormal PD-L1 glycosylation and degradation (17), and targeting N-glycosylation by 2DG or the combination of metformin and 2DG can decrease PD-L1 expression on tumor cells (57–60). This evidence concerns the gene CD274 and neoplasm.